{
    "2019-04-29": [
        [
            {
                "time": "2019-04-29",
                "original_text": "上海医药关于全资子公司药品通过仿制药一致性评价的公告",
                "features": {
                    "keywords": [
                        "上海医药",
                        "全资子公司",
                        "药品",
                        "仿制药",
                        "一致性评价"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-04-29",
                "original_text": "上海医药(02607)糖尿病药物“盐酸二甲双胍片”通过仿制药一致性评价",
                "features": {
                    "keywords": [
                        "上海医药",
                        "糖尿病药物",
                        "盐酸二甲双胍片",
                        "仿制药",
                        "一致性评价"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-04-29",
                "original_text": "上海医药:收入端显著提速，工商经营势头良好",
                "features": {
                    "keywords": [
                        "上海医药",
                        "收入端",
                        "提速",
                        "工商经营",
                        "势头良好"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-29",
                "original_text": "【国泰君安国际策略速评】上海医药2019年一季度收入增长26%至460亿元，商业部分超预期增长，管理层对业务发展充满信心",
                "features": {
                    "keywords": [
                        "国泰君安国际",
                        "上海医药",
                        "一季度",
                        "收入增长",
                        "商业部分",
                        "超预期增长",
                        "管理层信心"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-29",
                "original_text": "【东吴医药】医药周观点20190429:基金医药持仓比例11.3%，较2018年略有提升，建议积极关注有业绩保障的公司",
                "features": {
                    "keywords": [
                        "东吴医药",
                        "基金",
                        "医药持仓",
                        "比例提升",
                        "业绩保障"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-29",
                "original_text": "恒指高开0.43%报29730点 比亚迪股份绩后高开4.7%",
                "features": {
                    "keywords": [
                        "恒指",
                        "高开",
                        "比亚迪股份",
                        "绩后",
                        "涨幅"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "港股"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-29",
                "original_text": "香港恒生指数开盘涨0.43% 长和等涨逾1%领涨蓝筹股",
                "features": {
                    "keywords": [
                        "香港恒生指数",
                        "开盘涨",
                        "长和",
                        "蓝筹股"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "港股"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-04-29",
                "original_text": "【港股异动 | 上海医药高开逾5 一季度净利润增长10.42%至11.26亿元】",
                "features": {
                    "keywords": [
                        "港股异动",
                        "上海医药",
                        "高开",
                        "净利润增长"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}